Every five years, top officials of the Food and Drug Administration go behind closed doors to negotiate the terms of its core budget — about $3 billion this year. But the F.D.A. is not at the table with members of Congress or with White House officials. Instead, it’s in dozens of meetings with representatives of the giant pharmaceutical companies whose products the agency regulates.
Negotiations over legislation to reauthorize the FDA’s user fee programs will stretch into the weekend, according to two sources involved in the talks, as members remain at an impasse over adding extra policy provisions.